Senolytic Clearance Protocol (Research)

Selectively eliminate senescent cells via FOXO4–p53 disruption to reduce inflammaging and restore tissue function. Supported by immune clearance enhancement and telomere protection.

Patient profile: Research context only. Aged individuals (60+) with measurable senescent cell burden (elevated p16INK4a, SA-β-gal), chronic low-grade inflammation, or frailty phenotype. Not for general clinical use.

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol →

⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

FOXO4-DRI

Primary

Dose

Experimental — not established in humans

Frequency

3x/week SC (research protocol)

Timing

Morning, fasted

Duration

3 weeks, then minimum 9-week rest

Thymalin

Supporting

Dose

10 mg

Frequency

Daily SC

Timing

Morning

Duration

10 days (concurrent with first FOXO4-DRI cycle)

Epithalon

Optional

Dose

10 mg

Frequency

Daily SC

Timing

Evening

Duration

10 days

Monitoring Parameters

✓Senescence biomarkers: p16INK4a, p21 (if biopsy available), plasma GDF-15
✓Inflammatory panel: IL-6, TNF-alpha, CRP — baseline, week 3, week 12
✓Complete blood count — weekly during active phase
✓Renal and hepatic function (AST, ALT, creatinine, eGFR)
✓Frailty assessment (grip strength, 6-minute walk, Fried frailty index)
✓Telomere length (optional, research context)

Expected Outcomes

Week 3: Potential reduction in circulating SASP factors (IL-6, MMP-3) — detectable in labs

Weeks 6–8: Subjective improvement in energy, joint mobility, and cognitive clarity (reported in primate models)

Week 12: Reassessment of inflammatory panel and frailty markers — basis for decision on second cycle

Long-term: Theoretical reduction of tissue fibrosis and organ dysfunction burden over repeated annual cycles

Contraindications

✗TIER 4 — No human safety data. For research/educational purposes only.
✗Active or prior malignancy (theoretical risk: p53 pathway disruption)
✗Immunosuppression or active autoimmune disease
✗Active infection or fever
✗Pregnancy and breastfeeding
✗Concurrent cytotoxic therapy

Clinical Notes

FOXO4-DRI is a D-amino acid retro-inverso peptide with no approved human use. All dosing references are extrapolated from the landmark van Deursen/Kirkland mouse study (2017, Nature). Thymalin supports phagocytic clearance of apoptotic senescent cell debris by NK cells and macrophages — a critical step often overlooked in senolytic protocols. Epithalon is added for its documented telomerase-activating effect, addressing the related hallmark of shortened telomeres in aged tissue. The 3-week-on/9-week-rest cycle mirrors the pulse logic used in dasatinib+quercetin (D+Q) human trials. This protocol is a conceptual educational model only.

Case Study

Clinical Practice Example

Male, 67, presenting with elevated CRP (4.2 mg/L), plasma GDF-15 1,840 pg/mL (age-elevated), grip strength 28 kg (low-normal), and self-reported progressive fatigue over 18 months. Enrolled in a hypothetical research protocol. Baseline: p16INK4a mRNA elevated on peripheral blood mononuclear cells. After 3-week FOXO4-DRI cycle (experimental dose) + 10-day Thymalin: CRP 2.6 mg/L at week 12, GDF-15 1,480 pg/mL, grip strength 34 kg. Subjective energy rated 7/10 vs. 4/10 at baseline. Note: This is a hypothetical educational case — no real human trial data exists for FOXO4-DRI.

← Back to all protocols